{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:24:11Z","timestamp":1760833451344,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.breast.2023.103594","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T18:27:19Z","timestamp":1698690439000},"page":"103594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel\/carboplatin\/trastuzumab\/pertuzumab for HER2-positive breast cancer"],"prefix":"10.1016","volume":"72","author":[{"given":"Nalee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Joo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai-Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-7573","authenticated-orcid":false,"given":"Haeyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2023.103594_bib1","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.103594_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2023.103594_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Early Breast Cancer Trialists' Collaborative","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2023.103594_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2023.103594_bib9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4143\/crt.2021.901","article-title":"Real world evidence of neoadjuvant docetaxel\/carboplatin\/trastuzumab\/pertuzumab (TCHP) in patients with HER2-positive early or locally advanced breast cancer: a single-institutional clinical experience","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.breast.2023.103594_bib10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13014-015-0568-4","article-title":"Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update","volume":"10","author":"Budach","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1415340","article-title":"Regional nodal irradiation in early-stage breast cancer","volume":"373","author":"Whelan","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.103594_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1415369","article-title":"Internal mammary and medial supraclavicular irradiation in breast cancer","volume":"373","author":"Poortmans","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.103594_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijrobp.2013.03.021","article-title":"Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy","volume":"86","author":"Hennequin","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2023.103594_bib14","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaoncol.2021.6036","article-title":"Effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial","volume":"8","author":"Kim","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib16","first-page":"45","article-title":"Adjuvant locoregional radiation therapy in breast cancer patients with pathologic complete response after neoadjuvant chemotherapy: a systematic review and meta-analysis","volume":"33","author":"Nikyar","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2019.04.038","article-title":"Impact of radiation on locoregional control in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: results from ACOSOG Z1071 clinical trial","volume":"105","author":"Haffty","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2023.103594_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.breast.2023.02.006","article-title":"Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients","volume":"68","author":"Boersma","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2023.103594_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib20","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib21","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.21037\/gs-20-791","article-title":"Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study","volume":"9","author":"Lv","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.breast.2023.103594_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10549-021-06137-3","article-title":"Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study","volume":"187","author":"O'Shaughnessy","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2023.103594_bib23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-A rare event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"year":"2022","series-title":"Impact of postmastectomy radiation therapy on breast cancer patients according to pathologic nodal status after modern neoadjuvant chemotherapy","author":"Kim","key":"10.1016\/j.breast.2023.103594_bib24"},{"key":"10.1016\/j.breast.2023.103594_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205051","article-title":"Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis","volume":"14","author":"Swain","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2023.103594_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ijrobp.2020.06.078","article-title":"De-intensifying radiation therapy in HER-2 positive breast cancer: to boost or not to boost?","volume":"108","author":"Abi Jaoude","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2023.103594_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijrobp.2019.10.022","article-title":"Post-mastectomy radiation therapy in human epidermal growth factor receptor 2 positive breast cancer patients: analysis of the HERA trial","volume":"106","author":"Abi Jaoude","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2023.103594_bib28","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/cncr.26484","article-title":"Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer","volume":"118","author":"Kiess","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2023.103594_bib29","article-title":"Trastuzumab provides a comparable prognosis in patients with HER2-positive breast cancer to those with HER2-negative breast cancer: post hoc analyses of a randomized controlled trial of post-mastectomy hypofractionated radiotherapy","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4048\/jbc.2021.24.e33","article-title":"Impact of trastuzumab on ipsilateral breast tumor recurrence for human epidermal growth factor receptor 2-positive breast cancer after breast-conserving surgery","volume":"24","author":"Cheun","year":"2021","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.breast.2023.103594_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109668","article-title":"Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: pooled analysis of TRYPHAENA and NeoSphere trials","volume":"184","author":"Saifi","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.33525","article-title":"Hypofractionated volumetric-modulated arc therapy for breast cancer: a propensity-score-weighted comparison of radiation-related toxicity","volume":"149","author":"Kim","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2023.103594_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-021-06507-x","article-title":"Validation of a nomogram for predicting the risk of lymphedema following contemporary treatment for breast cancer: a large multi-institutional study (KROG 20-05)","volume":"192","author":"Byun","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2023.103594_bib34","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.103594_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.103594_bib36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2018.06.016","article-title":"Long-term impact of regional nodal irradiation in patients with node-positive breast cancer treated with neoadjuvant systemic therapy","volume":"102","author":"Stecklein","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2023.103594_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw331","article-title":"Regional nodal irradiation after breast conserving surgery for early HER2-positive breast cancer: results of a subanalysis from the ALTTO trial","volume":"109","author":"Gingras","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2023.103594_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jnci\/djx241","article-title":"RE: regional nodal irradiation after breast-conserving surgery for early HER2-positive breast cancer: results of a subanalysis from the ALTTO trial","volume":"110","author":"Belkacemi","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2023.103594_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.breast.2021.05.012","article-title":"Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy","volume":"59","author":"Cho","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.breast.2023.103594_bib40","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.22.00044","article-title":"Internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the Danish breast cancer group internal mammary node study","volume":"40","author":"Thorsen","year":"2022","journal-title":"J Clin Oncol"},{"volume":"37","year":"2019","author":"Mamounas","key":"10.1016\/j.breast.2023.103594_bib41"},{"key":"10.1016\/j.breast.2023.103594_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4048\/jbc.2022.25.e37","article-title":"Intensity modulated radiotherapy and volumetric modulated arc therapy in the treatment of breast cancer: an updated review","volume":"25","author":"Chang","year":"2022","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.breast.2023.103594_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113261","article-title":"Comparison of dose distribution in regional lymph nodes in whole-breast radiotherapy vs. Whole-breast plus regional lymph node irradiation: an in silico planning study in participating institutions of the phase III randomized trial (KROG 1701)","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:47:57Z","timestamp":1760777277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623005702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"alternative-id":["S0960977623005702"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.103594","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel\/carboplatin\/trastuzumab\/pertuzumab for HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.103594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103594"}}